ARCHIVES

In Brief: Daniel Ihde Named NCI Deputy Director; Roper Is Carter consultant; Another Honor For Forei

This article is from The Cancer Letter archive.

Vol. 17 No. 06 | February 8, 1991

Download PDF Visit The Full Archive

Related Articles

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

May 25, 2012

Assembly of Scientists, started as a result of conflict of interest controversy, plans Sept. 14 meeting.

September 9, 2005

Clinical Trials Approved By NCI CTEP Last Month

March 25, 2011

Reduced Risk of Metastasis When Screening Finds Cancer

August 27, 2004

Reports On AACR Scientific Sessions

May 21, 1976

ODAC Recommends Approval Of Paxen; Will IVAX Break Into $1 Billion Market

September 26, 1997